Author of

• 31515

  +

  P2.14 - Targeted Therapy (ID 183)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31525

    +

    P2.14-08 - Banf1 Predicts Lung Cancer Survival and Sensitivity to Platinum-Based Chemotherapy (ID 2146)

    10:15 - 18:15  |  Author(s): Jennifer Plowman
    • Abstract

    Background
    

    Barrier to autointegration factor 1 (BAF/Banf1) is a small, 10 kDa protein that functions as a non-specific DNA-binding homodimer and localises to the nuclear envelope during mitosis where it tethers DNA loops to the nuclear envelope.

    Mutations in Banf1 are associated with the severe premature ageing syndrome, Néstor–Guillermo Progeria Syndrome. Previously, key proteins associated with other progeria syndromes have been shown to play a role in both tumourigenesis and ageing, and now more recently, Banf1 expression has been associated with poor gastric cancer survival. With lung cancers being the leading cause of cancer-related deaths worldwide, identifying markers of improved prognosis, particularly in association with specific chemotherapy treatments, is essential to maximising drug effectiveness and promoting patient survival.

    Method
    

    A variety of cell and tissue biology techniques including cellular Banf1 protein depletion and overexpression in a panel of lung cancer cell lines, drug treatments, immunofluorescence, immunoblotting and tissue microarray analysis, have been utilised in this study.

    Result
    

    Kaplan-Meier analysis of mRNA datasets from 1926 patients diagnosed with lung cancer show a statistically significant association (p=7.8e-12) between “low” Banf1 mRNA and increased median overall survival of patients at 88.7 months, compared with the 52-month median survival of the “high” Banf1 mRNA cohort.

    Depletion of Banf1 in a panel of Non-Small Cell Lung Cancer (NSCLC) lines followed by cisplatin drug treatment demonstrated a heterogeneity of response, with a subset of cell lines experiencing improved survival while others displayed increased sensitivity to the drug compared with control cells.

    Conclusion
    

    Banf1 is a candidate marker of lung cancer patient prognosis with Banf1 depleted cells having altered sensitivity to cisplatin treatment. Understanding the mechanism by which Banf1 affects lung cancer cell sensitivity to this drug is an ongoing research process that may have major implications for lung cancer treatment. Identification of patient Banf1 expression levels may contribute to improved therapeutic tailoring while modulation of Banf1 expression may ultimately lead to significantly increased survival of diagnosed patients.